68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-21

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

NCT04831541

Prostate Cancer Positron-Emission Tomography

UNKNOWN EARLY_PHASE1

68Ga-FAPI PET/CT in Patients With Various Types of Cancer

NCT04499365

Tumor Positron-Emission Tomography Metastasis

UNKNOWN EARLY_PHASE1

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

NCT05637034

Tumor, Solid

UNKNOWN NA

Comparison of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT in Patients With Various Types of Cancer

NCT04941872

Tumor, Solid, FAPI, PET/CT, Metastasis

COMPLETED NA

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

NCT04588064

Lung Adenocarcinoma 18F-FDG 68Ga-FAPI +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with various types of cancer underwent 68Ga-BNU-PSMA PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga-BNU-PSMA PET/CT were calculated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor Positron-Emission Tomography Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

68Ga-BNU-PSMA

Each subject receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT imaging within the specificed time.

Group Type EXPERIMENTAL

68Ga-BNU-PSMA

Intervention Type DIAGNOSTIC_TEST

Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

68Ga-BNU-PSMA

Each patient receive a single intravenous injection of 68Ga-BNU-PSMA, and undergo PET/CT scan within specified time.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PET/CT scan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (i) adult population (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled 68Ga-BNU-PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee; (v) healthy volunteers(aged 18 years or order).

Exclusion Criteria

* (i) patients with pregnancy; (ii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes